About US
Contact us
-
Argenx pulls back curtain on Vyvgart trial win as part of mission to ensure 'no MG patient is left behind'A myasthenia gravis treatment revolution has taken place in the past four years, spurred by an initial approval for argenx’s first-in-class FcRn blocker Vyvgart at the end of 2021 and buttressed by a2025/10/31
-
Merck, Eisai scrap ambitions for Keytruda-Lenvima pairing in liver cancer subtype after survival missMerck & Co. and Eisai previously had high hopes for their Keytruda-Lenvima combination in a liver cancer subtype based on positive progression-free survival data, but now the combo’s promise has2025/10/31
-
Emma Walmsley upholds £40B sales target in her final GSK CEO reportEmma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40 billion-pound-sterling sales projection for 2031 on the back of a strong quarter. The GSK executives are2025/10/28
-
Innovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes, weight loss studyAn experimentalGLP-1/glucagon (GCP) dual receptor agonist from Eli Lilly and its Chinese partner, Innovent, has bested Novo Nordisk’s reigning GLP-1 semaglutide, in a phase 3 study across both blood2025/10/28
-
With FDA nod, Bayer's Lynkuet enters US market for nonhormonal menopause symptom medsFollowing a slight delay earlier this year—and a world-first green light in the U.K. over the summer—Bayer has clinched an FDA nod to bolster the limited arsenal of nonhormonal treatments for some of2025/10/23
-
For Sanofi, Dupixent's surge overcomes shortfall in vaccine salesOver the last 13 months, Sanofi and Regeneron have revved up the momentum for Dupixent, gaining three new indications for the anti-inflammatory agent. Friday, Sanofi reported that Dupixent had set a2025/10/23
-
CF buyers club aims to grow access to Vertex's Trikafta through trade-policy workaroundTo topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy Trikafta, a buyers club has resurfaced with a plan to introduce a discounte2025/10/21
-
Roche's Chugai strikes $200M M&A deal to take over IgAN asset in several Asian countriesAs the industry's competition in the rare kidney disease IgA nephropathy (IgAN) heats up in the U.S., Roche’s Chugai Pharmaceutical is making an M&A play to advance a leading contender across t2025/10/21
-
Novartis kicks off BTK competition in immunology with FDA approval for Rhapsido in chronic hivesNovartis has scored the FDA’s approval for a second BTK inhibitor that’s for a non-cancer indication, teeing off a potential competition with Sanofi down the line. The FDA hasblessedNovartis’ remibru2025/10/17
-
Merck unveils data from 2nd Winrevair PAH study previously halted for efficacyTwo clinical trials of Merck’s pulmonary arterial hypertension (PAH) drug Winrevair were so conclusive that the studies were halted within the last year because the efficacy of the treatment was assu2025/10/17